Co-Diagnostics shifts its Q3 2026 earnings release and investor webcast to November 10, 2026, two days earlier than the company's original announcement.
The company moved its Q3 2026 earnings release up to Tuesday, November 10, 2026, after market close, from the previously announced November 12. This is a scheduling change with no financial figures, guidance or business update, so it does not change the company's fundamentals. Any price effect should come only from the results themselves on the new date.
On Tuesday, November 10, 2026, after the market close, moved up from the previously announced November 12, with a conference call at 4:30 p.m. ET the same day.
The announcement contains no financial figures or guidance, so nothing in it points to good or bad results; it is only a change of date.
Co-Diagnostics, Inc. has rescheduled its third quarter 2026 financial results announcement to Tuesday, November 10, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, moving the event up by two days from the previously scheduled November 12 date.
Co-Diagnostics will report its Q3 2026 financial results on Tuesday, November 10, 2026, after the market close.
No, the announcement is strictly a scheduling change and does not contain financial figures, guidance, or business updates.